Skip to main content

Table 4 Clinical outcomes in HSV, CMV, HSV and CMV (co-reactivation) or non-reactivation groups

From: Herpes simplex virus and Cytomegalovirus reactivation among severe ARDS patients under veno-venous ECMO

 HSV reactivation (n = 40)CMV reactivation (n = 7)HSV and CMV reactivation (n = 20)Non reactivation (n = 56)
Duration of mechanical ventilatione (days)29 (19.5–41)a,b28 (20.5–37)a,b58.5 (38–72.3)a,c,d17.5 (9–28)b,c,d
Ventilator-free days at D28e (days)0 (0–0)0 (0–0)0 (0–0)0 (0–0)
Weaned from ECMO (%)23 (58)2 (29)15 (75)27 (48)
Duration of ECMOe (days)14 (9.75–20)a13 (9.5–16)19.5 (10.75–33)a9 (5–14)b,c
ECMO-free days at D28e (days)0 (0–16)0 (0–7)5.5 (0–17.25)0 (0–17)
ICU mortality (%)20 (50)5 (71)9 (45)33 (59)
Hospital mortality (%)20 (50)5 (71)10 (50)33 (59)
ICU length of staye (days)27.5 (17.75–35.5)b29 (20–30.5)b51.5 (32.5–69)a,c,d16 (8.75–30.25)b
Hospital length of staye (days)35 (26.75–56)b29 (23–44)70 (43.5–87)a,c24 (11–43)b
  1. Data are presented as median and interquartile range or absolute value and percentage
  2. ap < 0.05 compared with non-reactivation group
  3. bp < 0.05 compared with HSV and CMV reactivation
  4. cp < 0.05 compared with HSV reactivation
  5. dp < 0.05 compared with CMV reactivation
  6. eMedian, 1st–3rd quartile